Evidence map›Paper›PMID 35785042›Full record

ReviewRegenerative therapy2022

Safety of using cultured cells with trisomy 7 in cell therapy for treating osteoarthritis.

Mitsuru Mizuno, Nobutake Ozeki, Ichiro Sekiya

Open access · goldAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Regenerative therapy, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.6field-weighted citation impact, top 31% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 4 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 1 institution in 1 country.

Mitsuru MizunoCenter for Stem Cell and Regenerative Medicine, Tokyo Medical and Dental University (TMDU), 1-5-45, Bunkyo-ku, Yushima, Tokyo 113-8519, Japan.
Nobutake OzekiCenter for Stem Cell and Regenerative Medicine, Tokyo Medical and Dental University (TMDU), 1-5-45, Bunkyo-ku, Yushima, Tokyo 113-8519, Japan.
Ichiro SekiyaCenter for Stem Cell and Regenerative Medicine, Tokyo Medical and Dental University (TMDU), 1-5-45, Bunkyo-ku, Yushima, Tokyo 113-8519, Japan.
Tokyo Medical and Dental University · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Cell therapy is a promising alternative treatment approach currently under study for osteoarthritis (OA), the most common chronic musculoskeletal disease. However, the mesenchymal stem cells (MSCs) used in cell therapy to treat OA are usually expanded

Indexed as

ACAN, aggrecanaCGH, array comparative genomic hybridizationCDKN1A, cyclin-dependent kinase inhibitor 1ACDKN2A, cyclin-dependent kinase inhibitor 2ACell therapyCOL2A1, collagen type II alpha 1 chainCRP, C-reactive proteinEGFR, epidermal growth factor receptorFISH, fluorescence in situ hybridizationHGF, hepatocyte growth factorIL6, interleukin 6JACC, J-TEC autologous cultured cartilageKaryotypic abnormalityKIT, KIT proto-oncogene, receptor tyrosine kinaseMSC, mesenchymal stem cellMYC, MYC proto-oncogene, bHLH transcription factorOA, osteoarthritisOsteoarthritisPMDA, Pharmaceuticals and Medical Devices AgencyPPIA, peptidylprolyl isomerase ARA, rheumatoid arthritisSOX9, SRY-box transcription factor 9Synovial mesenchymal stem cellTrisomy 7

Identifiers

PMID35785042
PMCPMC9234008
OpenAlexW4283013453

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.